Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Infants with congenital heart defects have reduced brain volumes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic regulation of spermine oxidase activity and cancer risk: a Mendelian randomization study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Extrarenal expression of α-klotho, the kidney related longevity gene, in Heterocephalus glaber, the long living Naked Mole Rat

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vaccines against hepatitis C: a travel into neutralisation space

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration-response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC50) in different cell types: 7-12 µg/mL), followed by artemether (53-98 µg/mL), A. annua extracts (83-260 µg/mL) and artemisinin (151 to at least 208 µg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.

Original languageEnglish
Article number14571
JournalScientific Reports
Volume11
Issue number1
ISSN2045-2322
DOIs
Publication statusPublished - 16 Jul 2021

    Research areas

  • A549 Cells, Animals, Artemisia annua/chemistry, Artemisinins/pharmacology, COVID-19/drug therapy, Chlorocebus aethiops, Humans, Plant Extracts/pharmacology, SARS-CoV-2/drug effects, Vero Cells

ID: 66727254